Man-made superantigens: Tumor-selective agents for T-cell-based therapy

Area of Science:

• Immunology
• Protein Engineering
• Oncology

Background:

• Superantigens (SAgs) are potent immune stimulants.
• SAgs bind Major Histocompatibility Complex Class II (MHC II) on antigen-presenting cells, activating T-cells.

Purpose of the Study:

• To engineer a novel superantigen (SAg) for targeted cancer therapy.
• To improve the safety and efficacy of SAg-based immunotherapies.

Main Methods:

• Genetically linked tumor-specific antibody fragments to Staphylococcal enterotoxin A (SEA).
• Utilized structure-based drug design to mutate the MHC II binding site of SEA.
• Evaluated Fab-SEA fusion proteins and mutants in animal models for tumor targeting and T-cell activation.

Main Results:

• Fab-SEA fusion proteins targeted solid tumors and mediated T-cell-dependent tumor eradication.
• Native Fab-SEA caused dose-limiting toxicity due to systemic immune activation.
• Mutated Fab-SEA showed reduced MHC II retention and toxicity, with a >100-fold improved therapeutic window.

Conclusions:

• Protein engineering can convert toxic SAgs into safe, tumor-specific immunotherapeutic agents.
• Mutated SAgs offer improved targeting and reduced systemic toxicity for cancer treatment.